...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Circulation journal >Valsartan cardio-renal protection in patients undergoing coronary angiography complicated with chronic renal insufficiency (VAL-CARP) trial: rationale and design.
【24h】

Valsartan cardio-renal protection in patients undergoing coronary angiography complicated with chronic renal insufficiency (VAL-CARP) trial: rationale and design.

机译：接受冠状动脉造影并发慢性肾功能不全（VAL-CARP）的患者的Valsartan心脏肾脏保护试验：原理和设计。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Despite an increase in the frequency of coronary angiography (CAG) in Japan, the exact incidence of contrast-induced nephropathy (CIN) remains unknown in the Japanese population, especially in patients with chronic renal insufficiency. In addition, the nature of pharmacological interventions that would benefit the patients before or after procedures such as coronary bypass graft (CABG) and percutaneous coronary intervention (PCI) has not been fully investigated. METHODS: In the trial 500 patients with renal insufficiency (defined as a glomerular filtration rate (GFR) of between 89 and 30 ml . min(-1) . (1.73 m(-2)) following CAG will be randomly assigned to receive either valsartan, an angiotensin receptor blocker or angiotensin converting enzyme (ACE) inhibitor plus valsartan.1 The primary end-point is a change in the GFR of patients, which will be followed up for 3 years, including following CABG surgery or PCI. The incidence of cardiac events as well as the adverse effects of pharmacological intervention will be evaluated. In addition, the incidence of renal artery stenosis at the time of CAG will be reported also; however, the patients with renal artery stenosis will be excluded from the present study. CONCLUSION: The present study will provide data on: 1) the exact incidence and course of renal function of CIN after CAG; and 2) the comparative therapeutic benefit of pharmacological intervention with valsartan alone or with valsartan and an ACE inhibitor in combination in patients with coexisting coronary artery diseases and chronic renal insufficiency, regardless of whether they receive CABG or PCI. In addition to these studies, an estimate of the incidence of renal artery stenosis in these patients will be demonstrated.
机译：背景：尽管日本冠状动脉造影（CAG）的频率有所增加，但在日本人群中，尤其是在慢性肾功能不全的患者中，造影剂诱发的肾病（CIN）的确切发病率仍然未知。另外，尚未充分研究在诸如冠状动脉搭桥术（CABG）和经皮冠状动脉介入治疗（PCI）之类的手术之前或之后使患者受益的药物干预措施的性质。方法：在该试验中，将500名接受CAG的肾功能不全（定义为肾小球滤过率（GFR）在89到30 ml之间的患者（min（-1）。（1.73 m（-2）））随机分配为接受缬沙坦，一种血管紧张素受体阻滞剂或血管紧张素转换酶（ACE）抑制剂加缬沙坦。1主要终点是患者GFR的变化，将随访3年，包括CABG手术或PCI后。评估心脏事件的发生率以及药物干预的不良反应，此外，还将报告CAG时肾动脉狭窄的发生率;但是，本研究将肾动脉狭窄患者排除在外结论：本研究将提供有关以下方面的数据：1）CAG后CIN的确切肾功能发生率和病程。 2）单独使用缬沙坦或与缬沙坦和ACE抑制剂合用的药物干预对患有并存冠状动脉疾病和慢性肾功能不全的患者的相对治疗益处，无论他们是否接受CABG或PCI。除了这些研究之外，还将对这些患者中肾动脉狭窄的发生率进行估算。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号